Ingredients

Analysis of the opportunities and challenges in the biosimilars market.

From last-minute product inserts to putting out fires, close calls are a common occurrence.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.

RUSNANO, a corporation established by the Russian government to foster the development of nanotechnology, launched a project last week to manufacture targeted-delivery nanodrugs to treat malignant neoplasms.

The Society for Chemical Manufacturers and Affiliates offered its support for a Senate proposal to extend to 2015 current chemical-security standards, the Chemical Facility Anti-Terrorism Standards, which are set to expire this year.

Abbott Completes Acquisition Of Solvay; Merck Names President of Consumer Healthcare; And More.

Personalized medicine is still a nascent area for pharmaceutical companies, but several large companies recently reported developments in this area.

GSK Chief Executive Andrew Witty outlined the company's strategic priorities for 2010, which include further diversification into emerging markets, consumer healthcare, and vaccines.

Margaret Hamburg, commissioner of the US Food and Drug Administration, unveiled a new program to improve the efficiency of import inspections.

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

Pfizer's first updated pipeline since its acquisition of Wyeth includes fewer projects than before and is targeted to specific diseases.

Cephalon Buys Mepha; BASi's CEO Retires; and More.

AstraZeneca announced this week that it plans to undertake further restructuring in its research and development operations, resulting in the elimination of 3500 jobs.

The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.

Sharing too much-or too little-information can have disastrous onsequences.

As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

A look at the formulation challenges in pancreatic enzyme products.

Regulators and industry move to require inspections of API manufacturing facilities.

When it comes to healthcare rform, we must not overlook investment in innovative technologies.

How to cut time and cost by re-using already submitted documents.

Novartis CEO To Step Down; DSM To Close Netherlands Facility; And More.

Lonza Group (Basel) plans to reinforce its presence in Asia, including its platform in Nansha, China, and to close its Conshohocken (Riverside), Pennsylvania; Shawinigan, Canada; and Wokingham, United Kingdom, sites in 2010.

FDA Issues Warning Letter To McNeil Healthcare; Charles River Laboratories Will Suspend Operations At Massachusetts Facility.

The United States Pharmacopeial Convention is recalling USP 33?NF 28.

Bioject Medical Technologies establishes alliance with MPI Research; Biogen Idec CEO to retire; And More.

Team leaders in FDA's Office of Generic Drugs provide an overview.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.